Turning Point (TPB) Q3 2026 Earnings Call Transcript
Turning Point (TPB) reported Q3 2026 earnings, highlighting progress in consumer traction, distribution expansion, and infrastructure building. Net sales rose 27% YoY to $151M, driven by Modern Oral. Gross profit increased 21% to $85M, while adjusted EBITDA fell 41% YoY to $18M due to higher sales and marketing investments. Stoker's segment saw 52% YoY sales growth, with Modern Oral nicotine pouch sales up 103% YoY to $74M.
How this was made

The 30-second read
Why it matters
Earnings release provides fresh financial metrics and guidance on distribution expansion.
Market read
First earnings disclosure for Q3 2026, offering new data for traders.
What to watch
Potential future U.S. manufacturing start in 2027 could improve margins long-term.
Background
Turning Point Brands discussed strategic priorities, brand expansion, and supply chain investments during the call.
Ticker impact
Q3 2026 earnings released with net sales up 27% YoY to $151M and adjusted EBITDA down 41% YoY.
likely modest pressure as investors weigh strong sales against weaker profitability.
First report of quarterly results provides fresh data; market will price in revenue growth and EBITDA decline.
Market effects
Modern Oral nicotine pouch segment shows rapid growth, may boost peers in the category.
U.S. consumer discretionary sector may see mixed reaction due to strong sales but margin concerns.
Limited to U.S. market; no immediate global macro effect.
Counterpoint
Investors could view the EBITDA decline as a red flag and consider short positions despite sales growth.
Key entities
- companyTurning Point Brands
U.S.-listed consumer products company focusing on nicotine pouches.



